Ensysce gets Nasdaq extension on bid price; Cy deal triggers initial listing review

Ensysce Biosciences, Inc.

Nasdaq confirmed compliance with $2.5M stockholders' equity (Rule 5550(b)(1)) but requires evidence in next periodic report or delisting.
Bid price cure deadline extended to Feb 22, 2027; stock had been below $1.00 for 30 consecutive days.
Cy Biopharma acquisition deemed a Change of Control under Nasdaq Rule 5110(a); company must satisfy initial listing criteria.
Ensysce intends to submit an initial listing application to complete the Cy transaction and convert preferred shares.
Failure to meet listing requirements could lead to trading suspension of ENSC common stock.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.